Wuxi AppTec Group
WuXi AppTec Group is a public company founded in 2000 with headquarters in Shanghai, China. As a global company with operations across Asia, Europe and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. The company's integrated, end-to-end services include chemistry drug CRDMO, biology discovery, preclinical testing, clinical research and advanced therapies CTDMO, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform enables more than 6,000 customers from over 30 countries to improve the health of those in need and realize the vision that "every drug can be made and every disease can be treated.". Industries it has a preference for include: Diversified/Conglomerates, Biotechnology, Chemicals, Consumer Discretionary, Food & Beverage, Hardware, Healthcare, Healthcare Specialist, Industrial Machinery, Industrials, Information Technology, Medical Devices & Equipment, Pharmaceuticals, Raw Materials & Natural Resources, Software / Internet Verticals it has a preference for include: Artificial Intelligence (AI) / Machine Learning, Data Services, Cloud Computing, HealthTech, IoT (Internet of Things), Apps, Robotics, SaaS, RetailTech. It's preferred route(s) to market include: Primary Funds.